Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MVrLbY5ie2ViQYPzZZk> MVvJcohq[mm2aX;uJI9nKFCGR1[tbY5lfWOnZDDCdoRWKGmwY3;ydI9z[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC3JO69VQ>? NIW0WW8yOjZ2NkCxPS=>
3T3 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TBTGlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJIlv\HWlZXSgN3Q{KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xOSEQvF2= MnjQNVI3PDZyMUm=
3T3 NFe3UJFHfW6ldHnvckBCe3OjeR?= M4jwb2lvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiC5aYToJGlEPTBib3[gNE4xPSEQvF2= M2DXbVEzPjR4MEG5
3T3 MnS2T4lv[XOnIFHzd4F6 M336dFIxKG2rbh?= M1jpS2ROW09? MmG4R4VtdHWuYYKgbY5pcWKrdHnvckBw\iCYRVfGJIlv\HWlZXSgbJVu[W5iS1TSJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkKg{txO MlHqNVYyPjJyMEi=
NIH3T3 MmjXT4lv[XOnIFHzd4F6 NVLMZXV3OjBibXnu MVzEUXNQ M4O5dolvcGmkaYSgbJVu[W5iS1TSJItqdmG|ZTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEG4JO69VQ>? MmW3NVYyPjJyMEi=
A549 NVjWSXJHTnWwY4Tpc44hSXO|YYm= MlzrSG1UVw>? NV7kc4RLUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iQUW0PUBk\WyuIH3p[5JifGmxbjD3bZRpKEmFNUCgc4YhOiEQvF2= NUDTRXdUOTh2M{SxOFU>
DU145 M{HiN2Z2dmO2aX;uJGF{e2G7 MV\EUXNQ NHP6OlJKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=> Mk\4NVg1OzRzNEW=
KB3-1 Mmi2R5l1d3SxeHnjJGF{e2G7 MYW3NkBp M4LXVGROW09? MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> MX[xPVM6PzN{Mh?=
KBV1 NGn6PVFEgXSxdH;4bYMhSXO|YYm= MWm3NkBp MYnEUXNQ MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOge4l1cCCLQ{WwJI9nKDRwMTFOwG0> MkfaNVk{QTd|MkK=
A375 NFr2eZlEgXSxdH;4bYMhSXO|YYm= Mn7OO|IhcA>? M2D3NWROW09? MlyyTWM2OD13LkSg{txO NWXLUVRPOTl4NUS0NFg>
RS4-11 MlXmSpVv[3Srb36gRZN{[Xl? NGPRdZgzKGh? M{fX[GlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQTlizszN MUmxPVY2PDRyOB?=
RS4-11 MWTGeY5kfGmxbjDBd5NigQ>? MU[yJIg> M3G3bGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN2IN88US=> MWGxPVY2PDRyOB?=
Sf9 NEju[W9McW6jc3WgRZN{[Xl? M3i4flMxKG2rbh?= MXzJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVlXHSnIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlE5PSEQvF2= NFj5WnUyQTh3NEC1NS=>
Ba/F3 M2LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfnO|IhcA>? M4H5T2lEPTB;MT6yJO69VQ>? M365fFIxOTF5MEC0
BaPTC2 NYnqfmt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLwUHVSPzJiaB?= NYHiWmlRUUN3ME2wMlIzKM7:TR?= M4XmV|IxOTF5MEC0
Sf9 MlTQSpVv[3Srb36gRZN{[Xl? M4XXOFEhcA>? MmnwSG1UVw>? NXL1bpBJUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJHJGXCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOyEQvF2= NFj5d|gzODFzN{CwOC=>
H4 NWj6fXNES3m2b4TvfIlkKEG|c3H5 NYL2eFlQOTBizszN MYnUc5hq[2m2eTDpckBpfW2jbjDIOEBk\Wyucx?= MkLyNlA{PTB6ME[=
SF-539 MV7LbY5ie2ViQYPzZZk> NGjrToI{OzNizszN MV[2NEBucW5? NUXNeGZxTE2VTx?= MkDCTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxNk4zKM7:TR?= NVXRRZNtOjB2MEO3NFA>
U251 NVLReFM1U2mwYYPlJGF{e2G7 NIryWnk{OzNizszN MXq2NEBucW5? M{TQS2ROW09? M1\KRmlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMUiuPUDPxE1? NYS2ZXlkOjB2MEO3NFA>
A431 MoTMT4lv[XOnIFHzd4F6 MX\Jcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN MlLHNlA2PThyN{K=
A431 NHT4OppMcW6jc3WgRZN{[Xl? MVPJcohq[mm2aX;uJI9nKF[HR1\SNkBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEG4Mlkh|ryP M3T0O|IxPTV6MEey
HepG2 NU\tT45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NkBp NXvDcYppUUN3ME2zMlgyKM7:TR?= NV\vWmlEOjB3N{C1NlY>
Kasumi-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T0[|czKGh? NIrzUHdKSzVyPUCuNFE3KM7:TR?= MVeyNFU4ODV{Nh?=
RS4-11 NWjwNHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjOUXE4OiCq Ml7ETWM2OD1zIN88US=> MUKyNFU4ODV{Nh?=
THP1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT0dmNjPzJiaB?= M4fER2lEPTB;MD61JO69VQ>? M1jXXVIxPTdyNUK2
Kasumi-1 M1vY[WZ2dmO2aX;uJGF{e2G7 MnThTY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= M4DQXVIxQDN|MEO5
A549 M3XST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDINVYhcA>? M3TJTGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIO= M3HLN|IyPDVyNE[z
HL60 NW\6XZljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:1S|Y1OTZiaB?= NX3INI9TSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsdy=> NVnqfIZFOjF2NUC0OlM>
HUVEC NVy2[YlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\me4gyPiCq MVrJcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{Wg{txO NHTLS5IzOTR3MES2Ny=>
HUVEC NGXXd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;uVlE3KGh? NX;2cWo4UW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?= NGrCd5gzOTR3MES2Ny=>
IM9 M3P5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\FNVE3KGh? MoTSRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV25JINmdGy| MU[yNVQ2ODR4Mx?=
K562 NHLvNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[5V2syPiCq MWDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| NVv5dW1TOjF2NUC0OlM>
MDA-MB-231 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\TOFE3KGh? NHfueVVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy| NUHLd|RIOjF2NUC0OlM>
H460 M1LlNWN6fG:2b4jpZ{BCe3OjeR?= MoHwO|IhcA>? MoXPTWM2OD1{Lkeg{txO MljwNlE3OjF6OEC=
SMMC7721 M1zOfmN6fG:2b4jpZ{BCe3OjeR?= NHvXcoE4OiCq Ml;qTWM2OD14LkS3JO69VQ>? NIXNTokzOTZ{MUi4NC=>
WI38 MWXDfZRwfG:6aXOgRZN{[Xl? NUGwNollPzJiaB?= NIqwc2VKSzVyPUiuOVYh|ryP NGPHfIIzOTZ{MUi4NC=>
HEK293 MV3LbY5ie2ViQYPzZZk> Ml7PNVAxKG6P MkLNNUBp M164W4Rw\XNibn;0JIlvcGmkaYSgWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25ib3[geJlzd3OrbnWgNVE4PSC{ZYPp[JVmKG:wIG\FS2ZTOiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{ MYqyNVg5PTJ6Nx?=
HUVEC Mo\mSpVv[3Srb36gRZN{[Xl? NXzvR5dROSEQvF2= NITPWYIzPCCq MWDBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> NXrqbpNnOjF7NkOzNFU>
HUVEC M33aTGZ2dmO2aX;uJGF{e2G7 NV6wOJZWOSEQvF2= NVT2NZMyOSCq MlPKTY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE M2\uSVIyQTZ|M{C1
HUVEC Mnv3SpVv[3Srb36gRZN{[Xl? NV[2NlFROSEQvF2= MmDnNUBp MXTJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= MoSwNlE6PjN|MEW=
HUVEC Ml7TT4lv[XOnIFHzd4F6 M2\wSlEh|ryP NFjIRYIyKGh? MWLJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36gZZQhfHm{LUGxO|UhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD NGq2TmQzOTl4M{OwOS=>
HUVEC M1HjVmZ2dmO2aX;uJGF{e2G7 MYKxJO69VQ>? MmewNUBp M2LwboRw\XNibn;0JIlvcGmkaYSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtOFc{KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> M{PTOlIyQTZ|M{C1
HL60 MYnDfZRwfG:6aXOgRZN{[Xl? NGHKU242OCEQvF2= MnnUOFghcA>? MnO1SG1UVw>? MWLJR|UxRTF3LkWg{txO M4OzXFIzODF7MUi4
K562 NEHySIVEgXSxdH;4bYMhSXO|YYm= MWi1NEDPxE1? M4G0RVQ5KGh? NYPxemtYTE2VTx?= MUfJR|UxRTJzLkmg{txO NWHBNJRTOjJyMUmxPFg>
PC3 MUjDfZRwfG:6aXOgRZN{[Xl? NF3GbJo2OCEQvF2= NES1WZg1QCCq M{TYTmROW09? NUTadVJZUUN3ME2yOU4yKM7:TR?= NESwU2wzOjBzOUG4PC=>
SF-539 MWjLbY5ie2ViQYPzZZk> NXn1WGl1OzN|IN88US=> NF3G[GQ3OCCvaX6= M{jiZmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIT5do9{cW6nIHvpcoF{\SCjY4Tpeol1gSCrbjDQSGdHNUKELYP0bY12dGG2ZXSgbJVu[W5iU1[tOVM6KGOnbHzzJJdqfGhiSVO1NEBw\iBzMj6yJO69VQ>? NV:4XYViOjJ{MES3OFE>
HAEC M365Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n6VVExOCEQvF2= NUP3[FQ3PzJiaB?= NFPMd49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjBSWMh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5zIN88US=> NGHXXmwzOjR2NE[3PS=>
HT-29 NIfCWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNFAh|ryP M4XDVlczKGh? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHX4dJJme3OrbnegWmVITlJid3n0bEBKSzVyIH;mJFAvOzNizszN NGH3eVgzOjR2NE[3PS=>
MV4-11 NIn0dGxEgXSxdH;4bYMhSXO|YYm= NYLvPWg2PzJiaB?= MXXJR|UxRTBwMECzJO69VQ>? MlGwNlI1PTJ3MUi=
HepG2 NGm3NpREgXSxdH;4bYMhSXO|YYm= NYKzd3BwPDhiaB?= M3XCSGlEPTB;MUOuNlQh|ryP MmjDNlI1QDN4MEi=
PC9 M1SxSGN6fG:2b4jpZ{BCe3OjeR?= MUS0PEBp MV3JR|UxRTFyLkm3JO69VQ>? MXOyNlQ5OzZyOB?=
CAKI-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF63SHcyODBizszN NFzmOpU1QCCq MXPEUXNQ NU[w[ZhZT0l3ME2wMlY{KM7:TR?= MV:yNlU3ODZ{Nx?=
EKVX MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zK[|ExOCEQvF2= MUS0PEBp MkjiSG1UVw>? NWLFRY1bT0l3ME23Mlkh|ryP M{fkflIzPTZyNkK3
MCF7 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNFAh|ryP MX[0PEBp MkX1SG1UVw>? M3\wN2dKPTF;MjFOwG0> NVrlWYZtOjJ3NkC2Nlc>
MDA-MB-435 NYSxVJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PHelExOCEQvF2= MYO0PEBp NFT5V2FFVVOR NYjoWFRST0l3Mk2yJO69VQ>? NYfkeZJuOjJ3NkC2Nlc>
OVCAR3 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWyfoQyODBizszN MWi0PEBp M4XhTWROW09? MVTHTVU{RTNwMjFOwG0> MWiyNlU3ODZ{Nx?=
SNB19 NHPXcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXLOZMyODBizszN MoPuOFghcA>? NYX5c2N{TE2VTx?= MYDHTVU1RTFyIN88US=> MoPJNlI2PjB4Mke=
SW620 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnXVpdmOTByIN88US=> NIXWWpc1QCCq NEm2cHdFVVOR MWPHTVU2RTFwMzFOwG0> NW\QVI9HOjJ3NkC2Nlc>
TK10 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml76NVAxKM7:TR?= NFrGcHI1QCCq NVTzVY9{TE2VTx?= Mo\oS2k2Pj14LkOg{txO NV;oVll4OjJ3NkC2Nlc>
UACC257 M4fBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfISVhXOTByIN88US=> NWXQRWdkPDhiaB?= M4HRZ2ROW09? M{HoZmdKPTd;NDFOwG0> M3nUVlIzPTZyNkK3
HAEC MX3DfZRwfG:6aXOgRZN{[Xl? M1zFdlExOCEQvF2= MWe3NkBp M2[xemROW09? NELyc|dEgXSxdH;4bYNqfHliYXfhbY5{fCCYRVfGVkBmgHC{ZYPzbY5oKEiDRVOge4l1cCCLQ{WwJI9nKDBwMTFOwG0> MkTwNlMyOzF3NEG=
HT-29 NVT4OI9VS3m2b4TvfIlkKEG|c3H5 MkPoNVAxKM7:TR?= MYm3NkBp M{TsfGROW09? Mo\6R5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? M4PIPFI{OTNzNUSx
HCT116 NWHjR|NkTnWwY4Tpc44hSXO|YYm= MnfKNlQhcA>? MYPEUXNQ M3\qPWFvfGmvaXfyZZRwenliYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJI1q\3KjdHnvci=> NHmxSVMzOzF3M{KwNC=>
HUVEC MkO5SpVv[3Srb36gRZN{[Xl? MYiyJO69VQ>? MYGxPEBp M{fqRWROW09? NI[2d2xCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQ4OgeY5l\XJiaInwc5hq[yClb37kbZRqd25iYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvci=> M3\3SFI{OTV|MkCw
ACHN M{Hl[mN6fG:2b4jpZ{BCe3OjeR?= NX\w[IVFPiCm M1vve2lEPTB;Mj61JO69VQ>? M2jQSlI{OzZyMUC0
A498 M171e2N6fG:2b4jpZ{BCe3OjeR?= NVvyd|lWOTByIN88US=> MWC3NkBp MmLnSG1UVw>? MkfpTWM2OD12LkOg{txO NIPZUWszOzR6OU[yOi=>
HUVEC MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYizJO69VQ>? NEfXO5gzPCCq Mm\CSG1UVw>? NIf6R5lCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EB1fWKnIH\vdo1ifGmxbjD3bZRpKEWFNUCgc4YhOC54NEWg{txO NVWxR4doOjN3OEO5NVE>
HUVEC MUPLbY5ie2ViQYPzZZk> MVyyNFAh|ryP MYnEUXNQ MlfKTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= NEW1Z5EzOzV6M{mxNS=>
HUVEC M4Hy[WtqdmG|ZTDBd5NigQ>? NW\uR4VGOjByIN88US=> MkPRSG1UVw>? M{TuOWlvcGmkaYTpc44hd2ZiVlXHSnIyKHCqb4PwbI9zgWyjdHnvckBqdiCpcn;3eIgh\mGldH;yMZN1cW23bHH0[YQhUFWYRVO= NF3NblQzOzV6M{mxNS=>
A549 MnfFR5l1d3SxeHnjJGF{e2G7 MmPTO|IhcA>? NHTHUpRFVVOR NIm5dIFKSzVyPUKuOFQh|ryP M{\N[lI{PjB{NESx
HCT116 NUDPNYNpS3m2b4TvfIlkKEG|c3H5 MYG3NkBp NI\3TmxFVVOR NGPQNZVKSzVyPUSuO|Eh|ryP Ml\XNlM3ODJ2NEG=
MCF7 M3L4eGN6fG:2b4jpZ{BCe3OjeR?= M1XxbFczKGh? NV7HNo5HTE2VTx?= MWnJR|UxRTZwMkmg{txO NFH2OoszOzZyMkS0NS=>
BGC NFPT[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3O|IhcA>? MUDEUXNQ NF;DPYFKSzVyPUSuO|gh|ryP NWHHS|d[OjN7OUmwOFA>
BxPC3 M3K5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfaSXpMPzJiaB?= MlnJSG1UVw>? NVP0emp5UUN3ME2zMlY{KM7:TR?= M3[wcFI{QTl7MESw
HT-29 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nxOVczKGh? MVnEUXNQ MYfJR|UxRTFwNEeg{txO MUSyN|k6QTB2MB?=
T24 NUf2eIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp M3jTXWROW09? MXPJR|UxRTJwNESg{txO Mn3uNlM6QTlyNEC=
4T1 MnvVR5l1d3SxeHnjJGF{e2G7 MUe3NkBp M3H2V2ROW09? NVnVe2YyUUN3ME2wMlAyPiEQvF2= NYPrdnpVOjR6OUC2OVI>
MCF7 M4fNSGN6fG:2b4jpZ{BCe3OjeR?= Mn;yO|IhcA>? NVv4ZmhqTE2VTx?= NWHn[I1IUUN3ME2wMlAzPzFizszN NWfZ[|l3OjR6OUC2OVI>
MCF7 MnHUR5l1d3SxeHnjJGF{e2G7 MVW3NkBp MVXEUXNQ NVH3NWVkUUN3ME2wMlAzQTNizszN MmnnNlQ5QTB4NUK=
MDA-MB-231 M3z0fGN6fG:2b4jpZ{BCe3OjeR?= NVrqcoRUPzJiaB?= NEOxVnVFVVOR M2jEW2lEPTB;MD6wNlI{KM7:TR?= NVvnZXBTOjR6OUC2OVI>
MDA-MB-435 Mn3QR5l1d3SxeHnjJGF{e2G7 MlTIO|IhcA>? MoO5SG1UVw>? M4D1emlEPTB;MD6wNFk4KM7:TR?= M1;Q[lI1QDlyNkWy
MDA-MB-468 NIWwcYtEgXSxdH;4bYMhSXO|YYm= MUK3NkBp MV7EUXNQ M{jHcmlEPTB;MD6wNFYyKM7:TR?= MVOyOFg6ODZ3Mh?=
A431 MVHLbY5ie2ViQYPzZZk> MWSxNEDPxE1? NVvMZ4lSOSCq Ml;2SG1UVw>? Ml;sTY5pcWKrdHnvckBw\iCHR1\SJJdqfGhiSVO1NEBw\iByLkG3NlEh|ryP NGrHRmIzPDh7ME[1Ni=>
SH-SY5Y M1jDbWtqdmG|ZTDBd5NigQ>? M1n5[VExKM7:TR?= NVPFboV2OSCq NGXEdYdFVVOR MWXJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC5aYToJGlEPTBib3[gNE4xQDNzIN88US=> M1TWbVI1QDlyNkWy
U251 M2\5UGtqdmG|ZTDBd5NigQ>? MnW1NVAh|ryP NYrmNm02OSCq NUPoeotwTE2VTx?= M1n6OGlvcGmkaYTpc44hd2ZiVlXHSnIzKHerdHigTWM2OCCxZjCwMlAyQDlizszN MV6yOFg6ODZ3Mh?=
Bel7402 NUTDVFVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon3O|IhcA>? Mkm5SG1UVw>? NYXNOIZIUUN3ME2yMlY4KM7:TR?= MXSyOFkxPDl4MR?=
HK2 M3jHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXXT5I4OiCq NWnQXmVOTE2VTx?= MY\JR|UxRTVwOEWg{txO M37TNFI1QTB2OU[x
LO2 NYn3RXVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe3NkBp MVXEUXNQ M{H0VGlEPTB;MUmuPVMh|ryP NWD1XHp7OjR7MES5OlE>
MV4-11 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HOFghcA>? MVLEUXNQ NXrQVnBQUUN3ME2wMlAxOyEQvF2= MWSyOFkxPDl4MR?=
NCI-H3122 NULrV5pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MornO|IhcA>? MmDkSG1UVw>? NHyweGhKSzVyPUCuPFMh|ryP MkfaNlQ6ODR7NkG=
NCI-H460 NFfocnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPjdo04OiCq Mn;pSG1UVw>? NEi5[GpKSzVyPUSuN|Eh|ryP MXOyOFkxPDl4MR?=
NCI-H526 NGDDdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;nUIc4OiCq NF30eHNFVVOR NHzKXGZKSzVyPUGuNFEh|ryP MYqyOFkxPDl4MR?=
TT NUfwTo1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp NWnVVW9UTE2VTx?= MX\JR|UxRTBwMESg{txO NYK3S2R6OjR7MES5OlE>
EoL-1-cell M2ftTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TvNmlEPTB;MT62OEBxVQ>? MmC5V2FPT0WU
MV-4-11 NEfQSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rFXmlEPTB;MkeyJJBO MlTLV2FPT0WU
NOS-1 M3PFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32zZ2lEPTB;MUWuN{BvVQ>? Ml72V2FPT0WU
CGTH-W-1 NGCzOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHsSVVKSzVyPUOwMlk1KG6P M1;jR3NCVkeHUh?=
MONO-MAC-6 NUO1XGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrMTppKSzVyPUOzMlghdk1? Mmj4V2FPT0WU
ALL-PO M2TJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojMTWM2OD15OT64PUBvVQ>? Mn3FV2FPT0WU
NKM-1 NF;mc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTl6LkWyJI5O NYjodY4zW0GQR1XS
KM12 NUfpe29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Pac2lEPTB;M{WwMlE1KG6P Ml[2V2FPT0WU
TE-15 NWO5ZYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDyeWJKUUN3ME21NFcvPjFibl2= NGKzb4VUSU6JRWK=
697 NYDLTGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD14MUSuNlUhdk1? NXy0PXVDW0GQR1XS
MOLT-16 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTZ|MT6zNkBvVQ>? NUXZWWhtW0GQR1XS
GB-1 NVuyXHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PVVmlEPTB;N{GwMlI{KG6P MmG5V2FPT0WU
TE-12 NXO0ZldZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P3XGlEPTB;OEC0MlU2KG6P MYTTRW5ITVJ?
ES6 M4Pl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTl6MT6wOkBvVQ>? M3PzWHNCVkeHUh?=
LC-2-ad MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSySpB{UUN3ME2xMlEyPDB5IN88US=> Mli4V2FPT0WU
BL-70 NHj0R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXSOWhKSzVyPUGuNVE5PDZizszN MoHLV2FPT0WU
ETK-1 NVvDeo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1zLkK4OVgh|ryP NGnJUpRUSU6JRWK=
A4-Fuk M{LJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXlepdKSzVyPUGuN|QyPDFizszN NFXZd3lUSU6JRWK=
OCI-AML2 NG\Le4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXyTGNPUUN3ME2xMlM3QDVzIN88US=> NIqzcItUSU6JRWK=
SIG-M5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPXTWM2OD1zLkO3NFA6KM7:TR?= NWjLR5V6W0GQR1XS
NCI-SNU-16 NIKyVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi3SpBUUUN3ME2xMlQ3PDh4IN88US=> NEHpblBUSU6JRWK=
PSN1 M2TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwNUC2O|Yh|ryP NIW2e25USU6JRWK=
SR MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M360Z2lEPTB;MT61OFU4OiEQvF2= M3;ISnNCVkeHUh?=
A3-KAW MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwNkK1OFYh|ryP MnvBV2FPT0WU
KS-1 NXnoUlZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKwTWM2OD1zLk[5NlQ4KM7:TR?= NGG3Xo9USU6JRWK=
CTV-1 NWWyOGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jMbGlEPTB;MT63Nlc2OSEQvF2= M2W3fHNCVkeHUh?=
LB1047-RCC MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwOEG2NlQh|ryP MlnHV2FPT0WU
EMG-01 NUXFellbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELSUINKSzVyPUGuPFM2PjNizszN Ml7BV2FPT0WU
TE-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwOEO5PFUh|ryP M1XrdnNCVkeHUh?=
CMK NXHYR4loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrEVFdXUUN3ME2xMlk2PTF5IN88US=> M3TiVnNCVkeHUh?=
NB1 NIewblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zYRWlEPTB;MT65OlEyPyEQvF2= M{nDN3NCVkeHUh?=
HAL-01 NXmxbVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPKV2hKSzVyPUKuNFU6PDZizszN NF21fIVUSU6JRWK=
DEL M1HJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW2VGtKSzVyPUKuNFg1QDJizszN M3XzSnNCVkeHUh?=
RL95-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCbWdXUUN3ME2yMlEyOTN5IN88US=> NXfING01W0GQR1XS
KARPAS-299 M2[x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;6WHBKSzVyPUKuNVE{OTNizszN MkC2V2FPT0WU
EW-16 NV;xTWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwMUO1NFgh|ryP NIHvd3FUSU6JRWK=
RS4-11 NXfpZ4xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwMUe5NlQh|ryP M1XSUXNCVkeHUh?=
BB30-HNC NWn3OW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwMkKzO|Uh|ryP MYHTRW5ITVJ?
DOHH-2 M1K0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwM{O0N|Eh|ryP M1rNTXNCVkeHUh?=
RPMI-8402 M3nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfxWGlKSzVyPUKuN|M3OThizszN MmL0V2FPT0WU
BV-173 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP6TWM2OD1{LkOzOlYh|ryP Ml7WV2FPT0WU
TE-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1{LkO0N|g1KM7:TR?= M37CRnNCVkeHUh?=
TE-8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXHUotTUUN3ME2yMlM4ODN6IN88US=> NF3OXIhUSU6JRWK=
K052 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrHXJdSUUN3ME2yMlQxOjB{IN88US=> MX\TRW5ITVJ?
KARPAS-45 NH;PS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwNEm0OFYh|ryP Mn[yV2FPT0WU
SK-NEP-1 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hOI9oUUN3ME2yMlYxOjN5IN88US=> MUfTRW5ITVJ?
KGN Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OZWhUUUN3ME2yMlYxOzN7IN88US=> MVrTRW5ITVJ?
ML-2 NIq5fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHNUYpnUUN3ME2yMlY{PTF{IN88US=> NYriXVhWW0GQR1XS
LAMA-84 NH\hPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwNkm1OFUh|ryP M{XpOHNCVkeHUh?=
LXF-289 NEnTSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPsT3pKSzVyPUKuO|I6QDlizszN NVriVW95W0GQR1XS
A101D NX\2ZopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwN{izNFQh|ryP NHfmN5VUSU6JRWK=
KY821 NULhfGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETlfXZKSzVyPUKuO|k4PThizszN MYLTRW5ITVJ?
ES4 NXzrV|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj0TWM2OD1{LkiwOlI5KM7:TR?= NGLFcolUSU6JRWK=
SCC-3 NH;iOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwOEK4PVEh|ryP MUPTRW5ITVJ?
NALM-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPtXGlKSzVyPUKuPVA1PzNizszN M3vtT3NCVkeHUh?=
BL-41 M1zHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJwOUGyNlIh|ryP MU\TRW5ITVJ?
OPM-2 NF3IWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELuRllKSzVyPUOuNFU6PTRizszN M2m0Z3NCVkeHUh?=
SF126 NV\ERpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInNWpZKSzVyPUOuNFYyQThizszN NIrEfVRUSU6JRWK=
BE-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn5TWM2OD1|LkKzNVEyKM7:TR?= NFfqfodUSU6JRWK=
SF268 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\sSmlEPTB;Mz6zNlg3QSEQvF2= NELmOYJUSU6JRWK=
MOLT-4 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriTWM2OD1|LkO5PFM5KM7:TR?= NVrlV5BOW0GQR1XS
PF-382 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fsOGlEPTB;Mz60OFU4KM7:TR?= NEfIeHVUSU6JRWK=
HEL NELONWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwNEiwNFUh|ryP NUjGcGlYW0GQR1XS
RPMI-6666 NVrVPHNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjj[GVKUUN3ME2zMlU1OTdzIN88US=> NXrUfGhIW0GQR1XS
QIMR-WIL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH75V3hKSzVyPUOuOlM{QTFizszN NXzzUI04W0GQR1XS
ATN-1 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q5NWlEPTB;Mz62O|EyPCEQvF2= M{T3[XNCVkeHUh?=
BB49-HNC M13sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwN{C1NFgh|ryP Mkm0V2FPT0WU
HCE-4 NGXhNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\VbotYUUN3ME2zMlc5PjR{IN88US=> NUH4[WNOW0GQR1XS
SK-LMS-1 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf6VnJKSzVyPUOuPFM{OzhizszN M1HXWHNCVkeHUh?=
MS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDTTWM2OD1|LkizO|c5KM7:TR?= MWfTRW5ITVJ?
JAR MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwOUi4N|Ih|ryP MWHTRW5ITVJ?
KE-37 NWfsNI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj5UGRKSzVyPUSuNFYyPThizszN MnjQV2FPT0WU
LB996-RCC Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD12LkGyNVY5KM7:TR?= Mkf2V2FPT0WU
HH NXS2NlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTRwMkC5NVQh|ryP MYPTRW5ITVJ?
HL-60 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwMkGwOlUh|ryP NInk[3ZUSU6JRWK=
HOP-62 NEm2NnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDoTWM2OD12LkOzOVIh|ryP MlLjV2FPT0WU
NOMO-1 NYfUeZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRwM{O2PVkh|ryP NEHNSWNUSU6JRWK=
DU-4475 NIHGXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfl[5hKSzVyPUSuN|Y4OjlizszN MoHYV2FPT0WU
LC4-1 M132Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwM{iwO{DPxE1? NEPiWIxUSU6JRWK=
MC116 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vyeGlEPTB;ND60N|A5OSEQvF2= MmTkV2FPT0WU
SW982 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT3dIJKSzVyPUSuOVU{ODdizszN MWTTRW5ITVJ?
SK-N-DZ NFixVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjvVZQ1UUN3ME20MlY4ODl7IN88US=> NFvRelVUSU6JRWK=
EW-1 NYe4cZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG1THMzUUN3ME20MlY4QTFzIN88US=> NIH5N4xUSU6JRWK=
SU-DHL-1 NWDMUo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBeJNKSzVyPUSuPFAyPzRizszN MoTKV2FPT0WU
L-363 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX2PW5nUUN3ME20MlgxPjJzIN88US=> M1TEOHNCVkeHUh?=
OS-RC-2 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHQNXBKSzVyPUSuPFc{OSEQvF2= M13xfHNCVkeHUh?=
HD-MY-Z M1[0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTVwMUezNFEh|ryP M2nMUXNCVkeHUh?=
MHH-PREB-1 NHvQUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTVwM{KzNVIh|ryP NYTKdXU3W0GQR1XS
HC-1 M3XUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3HTWM2OD13LkSzNlkyKM7:TR?= M1;GdHNCVkeHUh?=
SK-MM-2 NHPMZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwNEe4NkDPxE1? NYLEWm1bW0GQR1XS
SH-4 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PKRWlEPTB;NT60PFM4KM7:TR?= MVHTRW5ITVJ?
MHH-CALL-2 NHfHSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTVwN{[3NVkh|ryP MYrTRW5ITVJ?
KG-1 M4XTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS3SldXUUN3ME22MlAzQDd6IN88US=> NU\TOplSW0GQR1XS
J-RT3-T3-5 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjQO29xUUN3ME22MlA4QTB7IN88US=> NVLpVoZtW0GQR1XS
MMAC-SF Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZwMUC5OFkh|ryP MoDzV2FPT0WU
IST-SL2 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwTY5yUUN3ME22MlEzPTF7IN88US=> NVLoS286W0GQR1XS
SW954 NYXXZoFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:xTWM2OD14LkK3OVE4KM7:TR?= NHu4T2NUSU6JRWK=
HDLM-2 M4izSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\NeGlEPTB;Nj6zNlExQSEQvF2= NFfXNmVUSU6JRWK=
ST486 M1XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjpUWdKSzVyPU[uN|Q4OSEQvF2= NWTLZWc{W0GQR1XS
DG-75 NGPPZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\VU3RbUUN3ME22MlQ{ODZ7IN88US=> M2HDbnNCVkeHUh?=
EW-3 M1nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi2dZBKSzVyPU[uOFMzODdizszN M{XlZXNCVkeHUh?=
8-MG-BA NVX0V3A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyOoV[UUN3ME22MlUyPTB5IN88US=> NHjsUGpUSU6JRWK=
GT3TKB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:5UlU2UUN3ME22MlYxPzZ|IN88US=> NYHoeodGW0GQR1XS
KU812 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTZwNkm0NkDPxE1? MnflV2FPT0WU
CESS M4PPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnaXlcxUUN3ME23MlExPDN6IN88US=> NFrsN4lUSU6JRWK=
BC-1 M3zETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjSVG9IUUN3ME23MlI1QDF{IN88US=> M3vFR3NCVkeHUh?=
MZ1-PC NEC1TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPlfVQ1UUN3ME23MlMxOzh7IN88US=> NEPOXlNUSU6JRWK=
NCI-H82 NHnFWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\iUXAxUUN3ME23MlM4QDVizszN MnXtV2FPT0WU
NCI-H1355 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\aTWM2OD15LkS1PFA1KM7:TR?= MUnTRW5ITVJ?
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTdwNUC3N|kh|ryP MV\TRW5ITVJ?
ARH-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfWR3ZrUUN3ME23MlU{PTl5IN88US=> NV;IcGg2W0GQR1XS
MN-60 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Tvd2lEPTB;Nz61OFA5QCEQvF2= NGTrcoFUSU6JRWK=
IMR-5 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXONYJKSzVyPUewOVQ5PzZizszN MVXTRW5ITVJ?
KARPAS-422 NHrINJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdwNUeyNFYh|ryP NVnDW5NKW0GQR1XS
CA46 NVPJ[JRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7lO5Q5UUN3ME23MlU5ODF{IN88US=> NWeye4x3W0GQR1XS
SJSA-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTdwNk[wOlEh|ryP NH\LWJlUSU6JRWK=
no-11 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPoTWM2OD15Lke3OVU4KM7:TR?= M{PUNnNCVkeHUh?=
IST-SL1 NUTYN2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHruZ5FKSzVyPUiuNFI1OTdizszN NXrSb2RnW0GQR1XS
NCI-H209 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHQdms2UUN3ME24MlEyPjV{IN88US=> NEfMZpRUSU6JRWK=
TALL-1 NGToNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDWY5KSzVyPUiuNVg{QDRizszN NFfh[oFUSU6JRWK=
KMOE-2 NWryUlh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\VTWM2OD16LkG5OFIh|ryP Mli5V2FPT0WU
HCC1599 NVrTRpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\jVGlEPTB;OD6xPVk5PyEQvF2= MonTV2FPT0WU
CI-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq0TWM2OD16LkKwOFEyKM7:TR?= M2HsTXNCVkeHUh?=
NCI-H1304 NIDleGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD16LkKwOlYyKM7:TR?= MVfTRW5ITVJ?
Daudi MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTTTWM2OD16LkKzOVQ3KM7:TR?= NYj6eoNHW0GQR1XS
CPC-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD0NGV2UUN3ME24MlI6OTl7IN88US=> NUjEbGVNW0GQR1XS
MC-CAR MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRThwM{O1PEDPxE1? MXzTRW5ITVJ?
SW872 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj3S5lkUUN3ME24MlM1PzV6IN88US=> MULTRW5ITVJ?
OVCAR-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3pTWM2OD16LkWwN|UyKM7:TR?= MmTVV2FPT0WU
OCUB-M NXq1OnluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHJNmVKSzVyPUiuOVY2ODhizszN M4PRNnNCVkeHUh?=
SK-PN-DW NYm0U|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK3VmhKSzVyPUiuOlA6QDVizszN M3fOVHNCVkeHUh?=
NCCIT NXnsc3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT1SmpKSzVyPUiuO|E4PDVizszN M{DwVnNCVkeHUh?=
NCI-H1648 NX;ZUXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTUTWM2OD17LkGzPFM1KM7:TR?= MWjTRW5ITVJ?
COR-L279 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTlwM{mwPUDPxE1? MYDTRW5ITVJ?
LS-123 NX\TbFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\z[GlEPTB;OT62PFE3OSEQvF2= MU\TRW5ITVJ?
LP-1 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlNndKSzVyPUmuO|gxQDNizszN MV;TRW5ITVJ?
NB13 M2XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP6RW1kUUN3ME25Mlc6QTl2IN88US=> M{DHPXNCVkeHUh?=
ONS-76 M1\afGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjScI9rUUN3ME25MlgyODF4IN88US=> MV\TRW5ITVJ?
VA-ES-BJ M2Hzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\UeWlEPTB;OT65PVk{OyEQvF2= MY\TRW5ITVJ?
GR-ST NEWwPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFyLkKyNFch|ryP NIjl[WxUSU6JRWK=
ES1 NWfVNINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;rTWM2OD1zMD6yPVg1KM7:TR?= MorZV2FPT0WU
NB14 NUHTXoZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fnXGlEPTB;MUCuPVI4PyEQvF2= M3L6WXNCVkeHUh?=
Ramos-2G6-4C10 NVnqPG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFzLkK2OUDPxE1? MV;TRW5ITVJ?
RXF393 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PDW2lEPTB;MUGuOFg{PCEQvF2= MmeyV2FPT0WU
NCI-H2107 M3vkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHaeGZKUUN3ME2xNU42QTh2IN88US=> NVzmcmhEW0GQR1XS
K562 M3n0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyNoZKSzVyPUGxMlg4ODJizszN MkS3V2FPT0WU
LOUCY MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX70bXR[UUN3ME2xNU46QDd3IN88US=> NIfw[pZUSU6JRWK=
TGBC1TKB NXLZW3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITmcnZKSzVyPUGyMlAxOiEQvF2= MXHTRW5ITVJ?
COLO-320-HSR MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD1zMj6xOVY2KM7:TR?= M1SwUXNCVkeHUh?=
K5 NIDsZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF{LkK5PFUh|ryP NHnE[nRUSU6JRWK=
BC-3 NFnoVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164WWlEPTB;MUKuOFY2OSEQvF2= M2WxXXNCVkeHUh?=
REH NGG5U3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH4TWM2OD1zMj62OFk5KM7:TR?= M2TS[3NCVkeHUh?=
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF{Lk[4PFch|ryP Mn65V2FPT0WU
IST-MEL1 NISwbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDJTWM2OD1zMj64Olk1KM7:TR?= NVTwTJhkW0GQR1XS
NCI-H128 NIXlOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL3T3VMUUN3ME2xN{4xPzJ|IN88US=> M1zIcXNCVkeHUh?=
NCI-H1694 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWzNYtGUUN3ME2xN{4yOTR2IN88US=> NXfETpNUW0GQR1XS
TGW NWroR|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF|LkOyO|Yh|ryP MU\TRW5ITVJ?
NCI-SNU-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|LkO0OUDPxE1? MUPTRW5ITVJ?
IST-MES1 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0UGZkUUN3ME2xN{43PzJ7IN88US=> NYTCNYV2W0GQR1XS
CTB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nSemlEPTB;MUOuO|I6PCEQvF2= MY\TRW5ITVJ?
HUTU-80 NXHCenJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF|Lke1O|Mh|ryP MVvTRW5ITVJ?
LAN-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF2LkK0OVch|ryP MmrOV2FPT0WU
KP-N-YS NGHLZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX0bGRKSzVyPUG0MlI5QTRizszN MWLTRW5ITVJ?
CCRF-CEM NHTlbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\DUVBKSzVyPUG0MlQyPjlizszN MlyzV2FPT0WU
NCI-H1770 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF2LkWzOlkh|ryP NYXkdnJpW0GQR1XS
MZ2-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;6TWM2OD1zNT6yNlUyKM7:TR?= NFq4RVVUSU6JRWK=
COR-L88 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnlTWM2OD1zNj6wNFEzKM7:TR?= M{f4RXNCVkeHUh?=
LOXIMVI MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPOTWM2OD1zNj6yOVYh|ryP NYHqcXBDW0GQR1XS
KALS-1 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\YT2lEPTB;MU[uOVk{OSEQvF2= NFXsWZJUSU6JRWK=
D-283MED NYXZd3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7KVXJKSzVyPUG2Mlg1QDlizszN MmrhV2FPT0WU
NCI-H719 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TGSGlEPTB;MU[uPVE3OSEQvF2= MVjTRW5ITVJ?
MLMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDh[VlqUUN3ME2xOk46QTB5IN88US=> NWHtN|RrW0GQR1XS
EVSA-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5[WlEPTB;MUeuNFQ5PSEQvF2= NH7rTJJUSU6JRWK=
SK-N-FI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7HWFJKSzVyPUG3MlY6OTNizszN MkTQV2FPT0WU
NTERA-S-cl-D1 NVL5VGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLGTWM2OD1zNz64OVczKM7:TR?= NV3ncYVTW0GQR1XS
NCI-H1882 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD1zNz65PFM1KM7:TR?= NV\SN4FpW0GQR1XS
A704 NIXETGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF5Lkm5NFQh|ryP MmjEV2FPT0WU
L-428 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnYTWM2OD1zOD6wNVUyKM7:TR?= MXjTRW5ITVJ?
HCC1187 NITsZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF6LkCxPFch|ryP M1ftZXNCVkeHUh?=
NCI-H1581 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezNXNKSzVyPUG4MlA5PjZizszN MXzTRW5ITVJ?
BB65-RCC NFjyS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Ptb2lEPTB;MUiuOFE3OiEQvF2= M2nE[XNCVkeHUh?=
EM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXETWM2OD1zOD61OlczKM7:TR?= M4XNTnNCVkeHUh?=
Raji MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF7Lkm1OlUh|ryP NF\xdXVUSU6JRWK=
TE-1 NGPDUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7KTWM2OD1{MD60NVA1KM7:TR?= Mnf0V2FPT0WU
SW962 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX5bWJKSzVyPUKwMlQzQTNizszN NICzWmhUSU6JRWK=
MHH-NB-11 NHHKS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJyLkW1NlEh|ryP MYfTRW5ITVJ?
no-10 M2izdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjkTWM2OD1{MT6wNlY1KM7:TR?= M{KxUnNCVkeHUh?=
GDM-1 NV[4eYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqTlJKSzVyPUKxMlk1OTRizszN NIPSO|RUSU6JRWK=
KMS-12-PE M4H5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XicmlEPTB;MkKuNlc1KM7:TR?= M2rKXXNCVkeHUh?=
NCI-H510A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD1{ND6xNlc5KM7:TR?= NVKzbYFxW0GQR1XS
ES5 M175dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ2LkezOFkh|ryP M{PFVHNCVkeHUh?=
JiyoyeP-2003 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fkUmlEPTB;Mk[uNlc1OiEQvF2= NX;DSZlCW0GQR1XS
NMC-G1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5R2lEPTB;MkeuNVgzOiEQvF2= NYC2OIM2W0GQR1XS
NCI-H446 NFzuR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;UTWM2OD1{Nz60PVQ3KM7:TR?= Mn36V2FPT0WU
NB7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1SmlEPTB;MkeuPVIzQSEQvF2= MkLnV2FPT0WU
A388 NGX1OI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2[GlEPTB;MkiuNFA4PCEQvF2= NWj6bpg2W0GQR1XS
JVM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ6LkK4PVgh|ryP NXnWeIxXW0GQR1XS
HT-144 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ6Lk[5JO69VQ>? MkDqV2FPT0WU
NCI-H747 NIr3V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ6LkmxPVUh|ryP MmGzV2FPT0WU
NCI-H1650 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Ec2lEPTB;MkmuNFE4PiEQvF2= MYfTRW5ITVJ?
EB-3 NUXDfmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3rTWM2OD1{OT61N|A6KM7:TR?= M2PS[XNCVkeHUh?=
KLE NX60[XNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXuRlZuUUN3ME2yPU43OTlizszN NFv2clhUSU6JRWK=
TK10 M1jUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[2TWM2OD1|MD6xNlYh|ryP MnrrV2FPT0WU
COLO-668 M{\rPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuwXY1DUUN3ME2zNE44QTJizszN MUfTRW5ITVJ?
NCI-H23 NXvjcpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjFNZlsUUN3ME2zNU4yODZ|IN88US=> MoP1V2FPT0WU
GOTO NFP2XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm2TWM2OD1|MT62NFg2KM7:TR?= NWq0N413W0GQR1XS
MSTO-211H MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjUJRKSzVyPUOxMlg3PzhizszN NYH0WJBZW0GQR1XS
LB831-BLC M{\Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPNTWM2OD1|Mj6zPFQ{KM7:TR?= NYHY[VduW0GQR1XS
SCH NF\4UnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjidY5vUUN3ME2zNk45PDh3IN88US=> MlH4V2FPT0WU
EHEB NWL0[m9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN2LkGxPVMh|ryP M{nh[3NCVkeHUh?=
U-266 NHTldYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGntb5hKSzVyPUO0MlI4QDFizszN M2fHSHNCVkeHUh?=
EW-11 NFfMUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj4TWM2OD1|ND60O|I2KM7:TR?= NWnzTphiW0GQR1XS
TE-9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1fGhVUUN3ME2zO{4xPDBzIN88US=> MXXTRW5ITVJ?
ES3 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnVOGJVUUN3ME2zO{42ODB2IN88US=> NETlOVNUSU6JRWK=
NCI-H2141 NUPDZZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN6LkC4OFMh|ryP NEDpR3BUSU6JRWK=
MPP-89 NUfrNIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\PTWM2OD12Mj6wOVg3KM7:TR?= Moj3V2FPT0WU
SK-MEL-2 M1XSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj2VI9KSzVyPUSyMlY1ODVizszN MUXTRW5ITVJ?
LC-1F M2jVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnp[WdKSzVyPUSzMlM3QDJizszN MmfxV2FPT0WU
NH-12 M17N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPkb2pPUUN3ME20N{46OzV7IN88US=> MWDTRW5ITVJ?
RKO MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2S|dKSzVyPUS0MlEzPTJizszN NWnyUJZSW0GQR1XS
KM-H2 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR2Lkm1O|ch|ryP MYHTRW5ITVJ?
SK-UT-1 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPjN3NKSzVyPUS5Mlg5OjVizszN MkX1V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01835158 Active not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) July 8 2013 Phase 2
NCT00381641 Active not recruiting Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Oncocytic Follicular Carcinoma|Unresectable Thyroid Gland Carcinoma National Cancer Institute (NCI) August 8 2006 Phase 2
NCT01061411 Completed Clear Cell Sarcoma of the Kidney|Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI)|Pfizer February 6 2010 Phase 1
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 5 2016 Phase 2
NCT00478426 Active not recruiting Endometrial Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7|Uterine Carcinosarcoma|Uterine Corpus Carcinosarcoma National Cancer Institute (NCI) April 30 2007 Phase 2
NCT03249740 Recruiting Neovascular Age-Related Macular Degeneration Graybug Vision August 29 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID